Skip to main content
. Author manuscript; available in PMC: 2013 Feb 28.
Published in final edited form as: J Neurosci. 2012 Aug 29;32(35):12051–12065. doi: 10.1523/JNEUROSCI.1857-12.2012

Figure 2. Characterization of the conditional Dab1 transgenic mouse.

Figure 2

A) Western blot of Dab1 expression in adult WT (Dab1+/+), homozygous floxed Dab1 (Dab1flox/flox), heterozygous floxed Dab1 (Dab1flox/+), homozygous Dab1 crossed with a conditional ubiquitous Cre-line injected with tamoxifen (UbiCreERT2/Dab1flox/flox+TMX) and heterozygous Dab1 crossed with a conditional ubiquitous Cre-line (UbiCreERT2/Dab1flox/+). b) Scheme of the conditional Dab1 knock out triple transgenic generation. Administration of TMX induces the removal of the dab1 expression cassette by Cre-mediated recombination and consequent expression of the β-galactosidase reporter. At the same time, the drug induces the expression of YFP in Nestin-expressing cells. C, D) Expression of the β-galactosidase reporter in adult-generated neurons in the DG after tamoxifen injection in adult NestinCreERT2/Dab1flox/flox mice. E–H) Expression of YFP in post-natally generated cells 7 weeks after injection of tamoxifen at P7-8 or P28-32 in NestinCreERT2/R26YFP/Dab1+/+ or NestinCreERT2/R26YFP/Dab1flox/flox mice. Arrows: Ectopically located cells. Arrowhead: Labeled glia in the hilus. I) Quantification of hilar ectopic DGCs showed increases in Nestin-CreERT2/dab1flox/flox mice treated with TMX at P7-8 (*,p<0.01) or P28-32 (*, p<0.001), and in Nestin-CreERT2/dab1flox/+ given TMX at P7-8 (*,p=0.001) versus TMX-treated Nestin-CreERT2/dab1+/+ controls (Con; early- and late-treated controls showed no difference and results were pooled).